About us & key figures
Our products are meant to derisk clinical development. We generate first-in-class molecules on the basis of unique patient-based assays for efficient treatment of diseases with high unmet medical needs.
Our Business Model
We create a pipeline of patient-based high-value programs in muscular and neurologic disorders as well as oncology. We develop them as collaborative proprietary programs in an open innovation model up to lead compounds.
Our patient-based assays are an intermediate exit/entry point, allowing industrial partners to get access to our programs at an early stage for their own drug discovery purposes.
Our Differentiating Features
Our capacity to develop AI-driven algorithms for image analysis allows us to use the full potential of complex patient-based disease models for drug discovery. Our ability to built synergistic precision networks around each of our programs maximises success. Our capability to align our efforts in an end-to end approach from early disease modelling up to first-in-class lead compounds is accelerating patient-based drug discovery. The combination of these three features is rendering Ksilink unique.
We aspire to become the leading biotech organization for patient-based phenotypic drug discovery. We aim to enable next generation medicine for diseases with high medical needs.
Everyday, our team partners with academia, hospitals and industry. We align our efforts and networks in order to drive patient-based drug discovery, in a faster and most synergistic way.
Discovering new drugs solving today’s unmet medical needs.
Advancing science by making outstanding expertise available and reliable for the pharmaceutical industry.
Achieving great outcomes faster by building precision networks in an integrated end-to-end approach.
Since 2014, over 50 Millions Euros have been invested into our programs
Our dedicated financing tools are translating scientific excellence into tangible results for the pharmaceutical industry.
A dedicated, multidisciplinary team of more than 20 experts
Our team is specialized in assay development, phenotypic screening, AI-driven image analysis, technology transfer, translational project management and coordination.
Outstanding platforms to accelerate patient-based drug discovery
Our programs benefit from a set of fully industrialized platforms. Their end-to-end alignment is one of our differentiating features.
Compounds for screening activities
Our cell-painted, annotated chemical compound libraries combined with large libraries of up to 200,000 compounds allow the discovery of first-in-class molecules.
high content images are used to validate our AI-based algorithms
Our fully integrated imaging and data-mining capacities are a guarantee for the development of biologically most relevant algorithms. They are key to render complex disease models applicable for large-scale phenotypic screening campaigns.
renowned partners are part of the Ksilink association
A synergistic mindset combining academic with clinical and industrial expertise is our key to success. All members of Ksilink are involved in our governance structures and actively contributing to what we call “next generation drug discovery”.
translational drug discovery projects partnered
Since 2014, Ksilink has initiated 15 collaborative programs gathering clinicians, academia and industry. Five patient-based disease assays were successfully established. Two attracted substantial funding for further development.
Our acceleration network counts more than 40 academic and industrial partners
We strongly believe in open innovation as the key to achieve greater outcomes. Ksilink is constantly extending its network of experts.